Twist Bioscience Shares Soar 10.27% to New High, Extending a Remarkable 493% Yearlong Rally Fueled by AI
Twist Bioscience Corp. shares rose 10.27% to $174.78, extending a 493% yearlong rally. The surge follows a data-services agreement with Eli Lilly's AI-driven drug discovery platform, TuneLab. The company raised full-year revenue guidance to $456M-$457M and aims for adjusted EBITDA breakeven by Q4. Despite strong growth, Twist remains unprofitable with a negative EBIT margin of 31.5%.
How this was made
The 30-second read
Why it matters
The new Eli Lilly data‑services deal and raised guidance could sustain momentum, but valuation and cash‑burn remain concerns.
Market read
The announcement fuels a notable intraday price surge and underscores AI's expanding role in biotech, making the stock a near‑term trading focus.
What to watch
Operating cash flow turning positive and low debt provide a cushion, but the company is still far from profitability.
Background
Twist Bioscience is a synthetic DNA company that has seen a 493% rally over the past year, driven by AI‑related news and partnership announcements.
Ticker impact
Twist Bioscience announced a new data‑services agreement with Eli Lilly and raised full‑year revenue guidance, driving a 10.27% price jump to $174.78.
Potential further short‑term upside if partnership execution is confirmed; watch for pull‑back on valuation concerns.
New contract and guidance are primary catalysts; the stock already showed strong momentum.
Market effects
Highlights growing AI‑driven demand in synthetic biology, potentially benefitting peers in biotech and contract manufacturing.
Positive for US biotech sector; may attract investor interest in AI‑enabled life‑science firms.
Shows cross‑industry AI collaboration (pharma‑biotech), signaling broader trend of AI integration in drug discovery.
Counterpoint
Valuation remains stretched relative to fundamentals; the rally may be driven more by short‑squeeze dynamics than sustainable earnings.
Key entities
- companyTwist Bioscience Corp.
Synthetic DNA technology firm.
- companyEli Lilly
Pharmaceutical company with AI‑driven drug discovery platform TuneLab.
